Mr. Kurdikar is the President and Chief Executive Officer of Embecta. Previously, he was the Worldwide President of Diabetes Care at BD. Prior to that role, he was the President and CEO of Cardiac Science Corporation (CSC), a global leader in the manufacturing and marketing of automated external defibrillators for public access markets. CSC had been acquired by a private equity firm via bankruptcy proceedings, and under Mr. Kurdikar's leadership, CSC returned to profitable growth and was sold in a successful exit to ZOLL Medical.
Prior to that role, Mr. Kurdikar was the Vice President and General Manager, Men's Health, within Urology and Pelvic Health at Boston Scientific. He was in the same role at American Medical Systems (AMS) and led the Men's Health business through a carve-out and sale to Boston Scientific, where he led the business through its integration. Before joining AMS, he served as Vice President, Marketing, at Baxter, and was previously Vice President, Marketing, for the Infusion Systems business for the U.S. region. In his 11 years with Baxter, he held leadership roles of increasing responsibility in finance, strategy and integration, R&D planning and operations. He began his career as a Senior Research Engineer at The Monsanto Company.
Mr. Kurdikar is currently a member of the Board of Directors of Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), AdvaMed (Advanced Medical Technology Association) and LMG Holdings (a portfolio company of The Riverside Company). He holds a Bachelor in Chemical Engineering from the University of Bombay (India), a Master of Science in Chemical Engineering from Washington State University, a Ph.D. in Chemical Engineering from Purdue University, and a Master of Business Administration from Washington University.
Mr. Kurdikar became President and Chief Executive Officer and a director of Embecta as of the Effective Time of the spin-off from BD on April 1, 2022, and has served on the Board since April 2022. The Company's independent directors expect to appoint him as Chairman of the Board, effective upon LTG (Ret.) David F. Melcher's departure from the Board at the Company's 2026 annual meeting of stockholders.